PUBLISHER: The Business Research Company | PRODUCT CODE: 1988768
PUBLISHER: The Business Research Company | PRODUCT CODE: 1988768
Bioanalytical testing services encompass cutting-edge methodologies for quantifying analytes. These services play a pivotal role in identifying and characterizing pharmaceuticals and metabolites within biological fluids such as blood, plasma, serum, urine, or tissue extracts.
Bioanalytical testing services encompass various essential tests, including ADME (absorption, distribution, metabolism, and excretion), pharmacokinetic, pharmacodynamic, bioequivalence, and bioavailability assessments. ADME examines how a chemical undergoes absorption, distribution, metabolism, and excretion within a living organism, crucial for understanding drug processing. It aids in evaluating safety, toxicity, and the viability of drugs, offering precise targets for future research and development endeavors. These testing services analyze both small and large molecules, catering to pharmaceutical and biopharmaceutical companies, contract development and manufacturing organizations, as well as contract research organizations. They serve as indispensable tools in drug development and assessment, providing vital insights into a compound's behavior within biological systems.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Tariffs are impacting the bioanalytical testing services market by increasing the cost of laboratory instruments, analytical devices, reagents, and specialized testing equipment sourced internationally, which raises overall service delivery expenses. Segments such as pharmacokinetic testing, pharmacodynamic analysis, bioequivalence studies, and ADME testing are particularly affected, especially across key pharmaceutical hubs in North America, Europe, and Asia Pacific. However, tariffs are also encouraging localized analytical infrastructure development and strengthening regional testing capabilities. Overall, tariffs create short term cost challenges while supporting long term regional resilience and technological advancement in bioanalytical testing services.
The bioanalytical testing services market research report is one of a series of new reports from The Business Research Company that provides bioanalytical testing services market statistics, including bioanalytical testing services industry global market size, regional shares, competitors with a bioanalytical testing services market share, detailed bioanalytical testing services market segments, market trends and opportunities, and any further data you may need to thrive in the bioanalytical testing services industry. This bioanalytical testing services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The bioanalytical testing services market size has grown rapidly in recent years. It will grow from $3.73 billion in 2025 to $4.11 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to growth in pharmaceutical r&d activities, rising demand for clinical drug testing support, increasing reliance on contract testing organizations, expansion of regulatory compliance needs, early development of analytical technology infrastructure.
The bioanalytical testing services market size is expected to see rapid growth in the next few years. It will grow to $6.27 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to rising biologics and biosimilar development, increasing clinical trial intensity worldwide, growing focus on precise pharmacokinetic assessment, expansion of personalized medicine initiatives, stronger emphasis on safe therapeutic validation. Major trends in the forecast period include increasing demand for drug assessment accuracy, rising focus on reliable quantification of analytes, growing expansion of outsourced bioanalytical testing, strengthening emphasis on regulatory standard compliance, increasing adoption of specialized biological sample analysis.
The rising government initiative to control infectious disease outbreaks is significantly contributing to the growth of the bioanalytical testing services market. The outbreak of the COVID-19 pandemic has aided in the growth in demand for bioanalytical testing services. Countries worldwide have been taking initiatives and increasing spending to prevent the spread and impact of the diseases. For instance, in March 2023, according to a report published by the Congressional Research Service, a US-based public policy research institute. The funding from National Institutes of Health (NIH) for Allergy/Infectious Diseases (NIAID) has increased from $6,323 million to $6,562 in 2023. Therefore, the rising government initiatives to control infectious disease outbreaks is driving the bioanalytical testing services market.
Major companies operating in the bioanalytical testing services market are focused on introducing advanced solutions, such as reverse transcription PCR (RT-PCR) tests, to sustain their position in the market. The reverse transcription PCR (RT-PCR) test is a laboratory technique that involves the conversion of RNA into complementary DNA (cDNA) using an enzyme called reverse transcriptase. For instance, in June 2023, Eurofins Scientific SE, a France-based testing laboratory company, launched the NovaType SARS-CoV-2 RT-PCR assay. The NovaType SARS-CoV-2 RT-PCR assay is clinically validated and has a short turnaround time, which is suitable for re-testing millions of positive samples to detect if the virus is a specific variant. It is a real-time reverse transcription PCR (RT-PCR) test designed for the qualitative detection of SARS-CoV-2, the virus that causes COVID-19, and the subsequent identification of specific variants, such as B.1.1.7 and B.1.351.
In August 2023, Scantox AB, a Denmark-based provider of bioanalytical and toxicology services, acquired Q&Q Labs AB for an undisclosed sum. Through this acquisition, Scantox AB seeks to enhance its bioanalytical service portfolio and broaden its capabilities in supporting drug development and safety evaluation. Q&Q Labs AB is a Sweden-based company that offers bioanalytical testing services, including pharmacokinetic, immunogenicity, and biomarker analyses for pharmaceutical and biotechnology firms.
Major companies operating in the bioanalytical testing services market report are CD BioSciences, Thermo Fisher Scientific Inc., Merck KGaA, Laboratory Corporation of America Holdings (LabCorp), Eurofins Scientific SE, ICON plc, PPD Inc., SGS SA, WuXi AppTec, Syneos Health Inc., Charles River Laboratories Inc., Intertek Group, Covance Inc., PAREXEL International Corporation, Medpace Holdings Inc., Almac Group, Pace Analytical Services LLC, Altasciences, BioAgilytix Labs, Frontage Laboratories Inc., Toxikon Inc., Absorption Systems LLC, Lotus Labs Pvt. Ltd., Bioneeds India Private Limited, Vipragen Biosciences Pvt. Ltd., Source BioScience
North America was the largest region in the bioanalytical testing services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioanalytical testing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the bioanalytical testing services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The bioanalytical testing services market includes revenues earned by entities by providing services such as method development, high throughput sample analysis, method validation, and pharmacokinetic and toxicokinetic support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Bioanalytical Testing Services Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses bioanalytical testing services market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for bioanalytical testing services ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bioanalytical testing services market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.